Pfizer报告说,2025年的Q1收入下降了7.8%,引用了Paxlovid销售下滑和利润下降。 Pfizer reports Q1 2025 revenue down 7.8%, citing Paxlovid sales slump and profit drop.

Pfizer的2025年Q1收入下降了7.8%,降至137.2亿美元,缺乏分析师的预期。 Pfizer's Q1 2025 revenue fell 7.8% to $13.72 billion, missing analysts' expectations. 该公司指出,其Paxlovid治疗的销售量下降,利下降9.9%. The company cited declining sales of its Paxlovid treatment and a 9.9% drop in profits. 尽管如此,辉瑞公司仍维持全年收入预测625亿美元,预计节省费用17亿美元。 Despite this, Pfizer maintained its full-year revenue forecast of $62.5 billion and projected cost savings of $1.7 billion. Pfizer的首席执行官指出,对潜在的Trump行政关税的不确定性正在阻碍美国业务的投资。 Pfizer's CEO noted that uncertainty over potential Trump administration tariffs is hindering investment in U.S. operations.